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ABSTRACT
Dysfunction of cognitive performance in schizophrenia has been associated with aberrant alteration of DNA methylation 
of several schizophrenia-risk genes. AKT1 and HTR2A are among the candidate genes for schizophrenia. Their 
expressions were found reduced in schizophrenia patients. Thus, we aimed to study the methylation status of AKT1 
promoter and HTR2A exon-I in Malaysian schizophrenia patients and their affected family members. In this study, each 
participant was required to perform Trail Making Test (TMT) part A and B to measure their cognitive performance. 
Genomic DNA extracted from the peripheral blood of 12 Malaysian schizophrenia families and 12 controls families, 
was subjected to bisulfite conversion. The methylation status of CpG sites of AKT1 promoter at Chr14: 104796054 and 
HTR2A exon-I at Chr13: 46896918 were identified using methylation-specific polymerase chain reaction (MSP). Our 
results showed that schizophrenia patients performed worse in both TMT-A and B (p<0.0001) than healthy controls. 
The patients also displayed significantly (p=0.023) high level of methylation in AKT1 promoter compared to controls. 
Meanwhile, no significant difference (p=0.248) in methylation status was observed in HTR2A exon-I between 
schizophrenia and control groups. Therefore, methylation of AKT1 promoter in peripheral bloods of patients may 
involve in cognitive impairment and schizophrenia pathology. In addition, we were able to demonstrate the heritability 
of DNA methylation status across family members.
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ABSTRAK
Disfungsi prestasi kognitif dalam skizofrenia telah dikaitkan dengan perubahan metilasi DNA pada beberapa gen yang 
berisiko menyebabkan skizofrenia. AKT1 dan HTR2A adalah antara calon gen kepada skizofrenia. Ekspresi gen-gen 
tersebut didapati berkurangan pada pesakit skizofrenia. Oleh itu, kertas ini bertujuan untuk mengkaji status metilasi 
promoter AKT1 dan exon-I HTR2A pada pesakit skizofrenia di Malaysia dan juga ahli keluarga mereka yang 
menghidap skizofrenia. Dalam kajian ini, setiap peserta dikehendaki melakukan Ujian Membuat Jejak (TMT) bahagian 
A dan B untuk mengukur prestasi kognitif mereka. DNA genom yang telah diekstrak daripada darah periferal 12 
keluarga skizofrenia di Malaysia dan 12 keluarga kawalan sihat, tertakluk kepada penukaran bisulfite. Status metilasi 
tapak CpG dalam promoter AKT1 di Chr14: 104796054 dan dalam exon-I HTR2A di Chr13: 46896918 dikaji dengan 
menggunakan metilasi-khusus tindak balas rantaian polimerase (MSP). Keputusan menunjukkan bahawa pesakit 
skizofrenia mendapat keputusan yang teruk dalam kedua-dua bahagian TMT-A dan B (p<0.0001) berbanding dengan 
kawalan sihat. Pesakit skizofrenia juga menunjukkan tahap metilasi promoter AKT1 yang tinggi secara signifikan 
berbanding dengan kawalan (p=0.023). Sementara itu, tiada perbezaan yang signifikan (p=0.248) diperhatikan dalam 
metilasi status exon-I HTR2A antara kumpulan skizofrenia dan kawalan sihat. Kertas ini menunjukkan bahawa metilasi 
promoter AKT1 dalam darah periferal pesakit skizofrenia mungkin terlibat dalam kecacatan kognitif dan patologi 
skizofrenia. Tambahan pula, kami dapat menunjukkan bahawa kewarisan status metilasi DNA dalam kalangan ahli 
keluarga.
Kata kunci: Metilasi DNA; prestasi kognitif; skizofrenia; Ujian Membuat Jejak
INTRODUCTION
Schizophrenia pathology involves the interaction between 
genetic and environmental factors (Gejman et al. 2010). 
The likelihood for an individual to develop schizophrenia 
is higher with the present of family history suffering the 
same psychiatric disorder (Nishioka et al. 2012; Salleh 
2004). Impairments in cognitive performance in 
schizophrenia patients remain stable throughout the course 
and these affect their quality of life (Bowie & Harvey 2006; 
Green et al. 2000). Deficit of processing speed has been 
proposed as the central feature to cognitive impairment in 
schizophrenia (Dickinson et al. 2007). Processing speed 
is defined as the time required by an individual to execute 
different cognitive operations. Several higher cognitive 
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functions are rely on this domain (Reichenberg & Harvey 
2007). Meanwhile, executive functions involve a set of 
mental processes consists of goal creation, planning, 
behavioral programming, and effective performance 
(Lezak 1987). Cognitive flexibility is part of the executive 
functions referring to the ability to shift back and forth 
between several tasks (Monsell 1996). 
The pathology of schizophrenia and cognitive 
impairment may be associated with dysfunction of 
epigenetic programs (Jones et al. 2013; Lee & Huang 
2016). Epigenetic processes such as DNA methylation 
influence the gene expression at transcriptional level 
(Gibney & Nolan 2010). The binding of methyl group to 
cytosine residues leads to transcriptional silencing (Gibney 
& Nolan 2010). DNA methylation are affected by genetics, 
age, sex, ethnicity, and economic status (Lam et al. 2012). 
Dysregulation of DNA methylation has been associated 
with several psychiatric disorders (Connor & Akbarian 
2008) and age-related cognitive dysfunction (Chouliaras 
et al. 2018; Marioni et al. 2015). Genome-wide DNA 
methylation analysis identified methylated CpG sites at 
promoters AKT1, NOS1, DNMT1, and SOX10 (Wockner 
et al. 2014). Several studies also found that the methylation 
in HTR2A promoter and exon-I was significantly altered 
in schizophrenia patients (Abdolmaleky et al. 2011; Cheah 
et al. 2017; Ghadirivasfi et al. 2011). Moreover, 
hypermethylated promoters was associated with reduced 
expression of schizophrenia-risk genes (Lee & Huang 
2016).
The AKT1, a serine-threonine protein kinase, is 
required for gamma-Aminobutyric acid (GABA)ergic 
neuron development and its activity is highly regulated by 
dopamine type 2 (D2) receptor (Souza et al. 2011). 
Dysregulation of AKT1 signaling due to DNA variants  is 
associated with schizophrenia pathogenesis (Bajestan et 
al. 2006; Ikeda et al. 2004; Schwab et al. 2005; Thiselton 
et al. 2008). Reduction in AKT1 expression in lymphocytes, 
hippocampus and frontal cortex of schizophrenia patients 
(Emamian et al. 2004), downregulation of AKT1 
phosphorylation levels in hippocampus as well as impaired 
hippocampal plasticity and function in mice with selective 
deletion of AKT1 (Balu et al. 2012), signify the role of 
AKT1 in modulating hippocampal neuroplasticity and 
function. 
Meanwhile, the HTR2A, is the primary cortical 
serotonergic receptors that linked to schizophrenia 
pathophysiology through dopaminergic pathway (Eggers 
2013). Serotonin regulates myriad processes in central 
nervous system (González-Maeso et al. 2007). Stress will 
induce excessive serotonin stimulation in the anterior 
cingulate cortex (ACC) and dorsolateral frontal lobe 
through HTR2A, leading to reduce brain plasticity (Eggers 
2013). Moreover, an excessive mesolimbic dopamine 
activity in normal ACC causes positive symptoms 
(Schwartz et al. 2012). Reduction in the expression of 
HTR2A and declined of HTR2A density in brain of 
schizophrenia patients, indicate its role in schizophrenia 
pathology (Dean & Hayes 1996; Garbett et al. 2008; 
Hurlemann et al. 2008). 
As schizophrenia and cognitive performance are 
associated with DNA methylation (Chouliaras et al. 2018; 
Lee & Huang 2016), we examine the relationship between 
cognitive impairments and DNA methylation patterns of 
AKT1 promoter and HTR2A exon-I in schizophrenia 
multiplex families. 
MATERIALS AND METHODS
SAMPLE COLLECTION
This study involved 12 schizophrenia multiplex families 
(n = 24) and 12 control families (n = 24). The multiplex 
families were comprised of 12 pro-bands and one of their 
affected first-degree relatives. All the patients were 
recruited from Hospital Permai Johor Bahru, Malaysia. 
They were diagnosed with schizophrenia as they fulfilled 
the criteria stated in the 4th edition of Diagnostic and 
Statistical Manual for Mental Disorders (DSM-IV) and 
interviewed by experienced psychiatrists using the Mini 
International Neuropsychiatric Interview (MINI). DSM-
IV was chosen due to its reliability in filed study (Frances 
2013; Vanheule et al. 2014). The patients participated in 
this study were absence of comorbidity. Meanwhile, 
healthy controls with psychiatric comorbidity, generalized 
anxiety disorder, predecessor history of illicit substance 
abuse, family history of neurodegenerative or psychiatric 
disorder, history of intellectual retardation, neurological 
disorder, or any clinical condition that could affect 
cognitive performance were excluded from this study. 
The participants are Malaysian citizens, comprising of 
three ethnic groups, i.e. Malay, Chinese and Indian. They 
were 18 years or older and were able to understand 
instructions of neurocognitive assessment. The 
demographical characteristics of all participants are 
presented in Table 1. Written consent was obtained for 
all participants. The study was approved by the University 
of Malaya Medical Center Medical Ethics Committee 
Institutional Review Board.
All participants were required to do Trail- Making 
Test (TMT) part A and B (Reitan 1992). TMT-A was 
completed by connecting 25 numbers that scattered on a 
page in ascending order by drawing a line. Meanwhile, for 
TMT-B, the subjects draw a line to alternately link the 
sequentially numbers and letters on a page. TMT is a 
commonly used test to measures processing speed, 
complex visual scanning, cognitive flexibility and 
executive functions (Tombaugh 2004). TMT-A is generally 
being used to measure processing speed (Salthouse 2011) 
while TMT-B is for cognitive flexibility and executive 
functions assessment (Mittal et al. 2013).  Meanwhile, the 
TMT derived scores (B: A and B-A/A) may represent a 
more useful indicator of executive control with relatively 
no influence of processing speed (Perianez et al. 2007).
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METHYLATION-SPECIFIC POLYMERASE CHAIN 
REACTION (MSP)
Genomic DNA was extracted from the peripheral blood 
using QIAmp DNA Blood Mini kit (Qiagen, USA). The 
methylation of specific single CpG site in AKT1 promoter 
(Chr14: 104796054) and HTR2A exon-1 (Chr13: 
46896918) was determined using methylation-specific 
polymerase chain reaction (PCR) (MSP). Firstly, AKT1 
promoter and HTR2A exon-1 regions were identified using 
ENSEMBL (http://asia.ensembl.org/index.html). Next, 
based on the desired gene sequences, four sets of primer 
sequences (Table 2) were designed using MethPrimer 
(http:/ /wwww.urogene.org/cgi-bin/methprimer/
methprimer.cgi) to amplify the two regions. Then, bisulfite 
conversion was performed using the MethylEasy™ DNA 
Bisulfite Modification kit (Takara Bio USA, Inc), according 
to the manufacturer’s standard protocol. MSP was 
performed in a total of 25 µL reaction volume containing 
1 µL bisulfite-converted DNA, 0.3 µM of each primer, 
12.5 µL of 2X MSP buffer (Episcope® MSP kit, TAKARA 
Bio Inc, Japan) and 0.6 µL MSP enzyme (Episcope® MSP 
kit, TAKARA Bio Inc, Japan). The amplification started 
with 30 s initial denaturation at 95 ºC, followed by 40 
cycles of amplification (denaturation at 98 ºC for 5 s, 
primers’ annealing temperature as stated in Table 2 for 1 
min and extension at 72 ºC for 1 min) and a final extension 
at 72 ºC for 7 min. Finally, the PCR products were run on 
3% agarose gel and visualized under UV light. 
All MSP products were cloned using NEB PCR 
Cloning kit (New England Biolabs, Inc) and transformed 
into the NEB 10-beta competent Escherichia coli following 
the manufacturer’s instruction. After an overnight 
incubation at 37 ºC, colonies were screened using colony 
PCR according to manufacturer’s protocol for further 
confirmation. The PCR products were run on 2 % agarose 
gel and visualized under UV light. The products of colony 
PCR were sequenced to verify the results of MSP.
STATISTICAL ANALYSIS
The obtained data were analyzed using Statistical Package 
for the Social Sciences (SPSS) for Windows 14.0 (SPSS 
Inc., Chicago, IL, USA) with the significant differences at 
p<0.05. The continuous and categorical variables were 
analyzed by Student’s t-test and chi-square/Fisher’s exact 
test, respectively.
RESULTS AND DISCUSSION
COGNITIVE PERFORMANCE
Analysis of the TMT data showed that the patients took 
significantly (p<0.001) longer time to complete TMT-A 
and B tasks compared to the healthy controls. Besides the 
TMT direct scores, the patients also obtained significantly 
(p<0.05) higher TMT derived scores (B-A, B-A/A, B:A) 
than the control group (Table 3). Another study also found 
that schizophrenia patients performed poorer in both 
TMT-A and B tasks and the differences in the TMT derived 
scores between patients and healthy controls were 
significant (Perianez et al. 2007). This demonstrated that 
the processing speed, cognitive flexibility and executive 
function of schizophrenia patients were below average 
compared with the healthy people. 
METHYLATION STATUS OF AKT1 PROMOTER AND          
HTR2A EXON-I
In total, 8 CpG dinucleotides present in the AKT1 promoter 
(Figure 1(a)). However, only one of the CpG dinucleotides 
was found at the priming sites (Figure 1(b)). These results 
were further confirmed by sequencing analysis. The 
majority of the schizophrenia patients and healthy subjects 
had methylated cytosine residue at this CpG site. However, 
the detection rate was significantly higher (p=0.023) in the 
patients (Table 4). Nevertheless, sequencing analysis 
revealed that all of other 7 CpG sites were unmethylated 
in both patients and healthy control groups (Figure 1(c)).
Our findings were supported by a genome-wide DNA 
methylation study, which found that AKT1 was differentially 
methylated near the promoter region in schizophrenia 
patients (Wockner et al. 2014). The methylated DNA 
promoter has been associated with aberrant transcriptional 
silencing and reduced gene expression (Herman & Baylin 
2003; Razin & Cedar 1991). This is thought being regulated 
by at least two mechanisms. The first one is the methylation 
of CpG dinucleotides which will prevent the binding of 
transcription factors to the promoter, thus suppressing the 
gene transcription (Long et al. 2017).  
Secondly, the methylated CpG regions will be 
identified by the methyl-CpG-binding proteins (MeCPs), 
for an example MeCP1 (Lewis et al. 1992), which later 
may recruit histone deacetylases to repress gene regulation 
(Jones & Laird 1999). Several studies have shown a 
TABLE 1. Demographical data of all subjects
Scz (n = 24) HC (n = 24)
Mean ± SD Mean ± SD
Age (years) 40.04 ± 9.81 35.91 ± 12.18
Age at onset (years) 29.61 ± 8.60 -
Illness duration (years) 11.56 ± 7.14 -
Education (years) 9.13 ± 2.55 14.10 ± 4.40
HC: healthy controls; n: total number of samples; Scz: schizophrenia; SD: standard deviation
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reduction in AKT1 expression in lymphocytes-derived cell 
lines (Emamian et al. 2004), peripheral blood mononuclear 
cells (van Beveren et al. 2012) and  brain (Thiselton et al. 
2008) of schizophrenia patients. Thus, the reduction in 
AKT1 expression in schizophrenia patients might be due 
to the methylation of AKT1. Reduced AKT1 activity may 
lead to the dysregulation of glycogen synthase kinase-3β 
(GSK3β) signaling and consequently, negatively affecting 
the neuronal function and synaptic plasticity (Emamian et 
al. 2004). In addition, the deficiency of AKT1 was reported 
to be associated with the modulation of GABAergic 
interneurons and GABAA receptor expression, leading to 
the impairment of hippocampus-dependent cognitive 
functions (i.e. spatial memory) (Chang et al. 2016). 
Serotonin, a known neurotransmitter, activates the 
PI3K/AKT/mTOR/p70S6K phosphorylation signalling 
through G-protein-coupled receptors (Zamani & Qu 2012). 
As shown in an in vivo study, reduction of AKT1 activity 
in schizophrenia patients may negatively impact the 
activation of HTR2A by serotonin via β-arrestin2/
phosphoinositide 3-kinase/Src/Akt cascade (Schmid & 
Bohn 2010). Therefore, methylation of CpG site in AKT1 
promoter may be associated with schizophrenia 
pathophysiology. As the patients had a higher rate of 
methylated cytosine residue at CpG sites of the AKT1 
promoter compared to healthy controls, we hypothesized 
that AKT1 promoter methylation might be associated with 
the impairment of cognitive performance show by the 
TABLE 2. Primers for MSP analyses of the target genes
Genes Primer sequences (5’→ 3’) Ta (ºC) Fragment sizes (bp)
AKT1 (Chr14: 104796033-104796133)
UM F GGGTAGTTTGAAAGTTAATTTAAG 57 101
R TAACCCTAACAAAAAAAACCCA
M F GGGTAGTTTGAAAGTTAATTTAAG 57 101
R TAACCCTAACAAAAAAAACCCG
HTR2A (Chr13: 46896918-46897029)
UM F AATTAGGAGTTTTTTGGTGTAGAT 56 134
R CTAAATTCCTCCCTCCCTATACA
M F AATTAGGAGTTTTTTGGTGTAGAT 56 134
R CTAAATTCCTCCCTCCCTATACG
bp: base pair; F: forward primer; M: methylated; R: reverse primer; Ta: annealing temperature; UM: unmethylated. The underlined letters indicate cytosine at CpG sites
TABLE 3. Comparison of cognitive performance in schizophrenia patients and healthy control subjects
Scz (n=24) HC (n=24) t df p
Mean±SD Mean±SD
TMT-A 52.82 ± 23.44 28.05 ± 9.74 4.692 45 <0.001
TMT-B 140.61 ± 94.13 51.81 ± 20.79 4.420 45 <0.001
B-A 87.79 ± 82.36 22.76 ± 17.56 3.648 45 0.001
B-A/A 1.73 ± 1.34 0.93 ± 0.62 2.613 45 0.012
B:A 2.73 ± 1.34 1.93 ± 0.62 2.613 45 0.012
df: degree of freedom; HC: healthy control; n: sample size; Scz: schizophrenia; SD: standard deviation; t: Student’s t-test.
TABLE 4. DNA methylation statuses of AKT1promoter and HTR2A exon-1 in the peripheral blood of schizophrenia patients and 
healthy subjects
Gene Methylation status Scz (n=24) HC (n=24) p
AKT1 (Chr14: 104796054) 0.023a
Unmethylated 1 (4.2%) 8 (33.3%)
Methylated 23 (95.8%) 16 (66.7%)
HTR2A (Chr13: 46896918) 0.248b
Unmethylated 10 (41.7%) 14 (58.3%)
Methylated 14 (58.3%) 10 (41.7%)
HC: healthy control; n: sample size; Scz: schizophrenia. a Fisher’s exact test; b Chi-square test
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patients. This could be observed in the current study, where 
schizophrenia patients with impaired cognitive performance 
showed methylated CpG at AKT1 promoter.
For HTR2A exon-I, only one CpG dinucleotide of the 
amplified HTR2A could be identified at the priming sites 
(Figure 1(e)). Although majority of the patients had 
methylated CpG, the difference was not significant 
(p=0.248) compared to healthy controls (Table 4). This 
finding is consistent with the results obtained by Cheah et 
al. (2017) for this CpG site. Their study using post-mortem 
frontal cortex brain tissue demonstrated that there was no 
significant difference in the methylation status at this CpG 
site in schizophrenia and healthy subjects (Cheah et al. 
2017). The cloning and sequencing analysis also showed 
that the other three CpG dinucleotides present in the first-
exonic region of HTR2A were unmethylated in both 
schizophrenia patients and healthy controls (Figure 1(f)). 
This demonstrated that these CpG sites might not be 
associated with schizophrenia pathology and reduced 
cognitive performance in the current study. However, the 
dysregulation of HTR2A expression in schizophrenia 
patients might be caused by other factors such as promoter-
region-hypermethylation or genetic variants. An inverse 
correlation between HTR2A expression and its promoter 
methylation level was observed by Abdolmaleky et al. 
(2011). Besides that, several studies found a significant 
association of single nucleotide polymorphisms (SNPs) 
rs6311 and rs6313 in schizophrenia patients (Gu et al. 
2013; Sujitha et al. 2014; Tee et al. 2010; Williams et al. 
1996). The SNP rs6311 that located in the promoter region 
of HTR2A is proposed to cause reduced promoter activity 
and consequently may affect the gene transcription (Myers 
et al. 2007). Meanwhile, SNP rs6313 in the first exonic 
region of HTR2A may lead to reduce mRNA levels and 
thus, deficient protein synthesis (Myers et al. 2007). 
Deregulation of HTR2A expression caused by promoter 
hypermethylation and genetic polymorphisms may lead to 
impaired cognitive performance in schizophrenia. This is 
because, as activation of HTR2A in the prefrontal cortex 
was able to enhance the GABAergic neuron activity (Abi-
Saab et al. 1999; Shen & Andrade 1998), hence deregulation 
of HTR2A expression may affect working memory 
functioning regulated by these neurons (Volk & Lewis 
2005). However, the TMTs used in the current study did 
not assess working memory of the subjects. This may 
explain the possibility of no association between HTR2A 
exon-I methylation and patients’ impaired processing 
speed, cognitive flexibility and executive functions. 
The methylation patterns of AKT1 promoter as well 
as HTR2A exon-I were compared among family members. 
Majority of schizophrenia family members shared similar 
DNA methylation status in AKT1 promoter and HTR2A 
exon-I (Table 5). Another study also showed that the 
methylation status of HTR2A at first exonic region was 
similar between the patients and their first-degree relatives 
(Ghadirivasfi et al. 2011). Moreover, unaffected family 
FIGURE 1. Sequence of MSP products. The sequence of (a) AKT1 promoter retrieved from ENSEMBL, (b) methylated CpG site 
in AKT1 at Chr14: 104796054, and (c) unmethylated CpG site in AKT1 at Chr14: 104796054. The sequence of (d) HTR2A exon-I 
retrieved from ENSEMBL, (e) methylated CpG site in HTR2A at Chr13: 46896918, and (f) unmethylated CpG site in HTR2A at 
Chr13: 46896918. The underlined dinucleotides are CpG sites and the arrow shows the cytosine residue after being treated with 
bisulfite
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members of schizophrenia patients showed a predisposition 
for the same aberrant alteration of DNA methylation, which 
might be due to shared genetic or environmental factors 
(Abdolmaleky et al. 2015). This proved that DNA 
methylation is heritable.
Several limitations should be considered in evaluating 
these findings. Firstly, this study was conducted with a 
very small sample size. The results may not reflect the 
overall Malaysian schizophrenia population. Secondly, 
there was limited information on patients’ social-
demographic factors such as medication histories and their 
occupation. Antipsychotic medication was suggested as 
one of the factors that could affect the gene methylation 
patterns. For an example, drugs such as valproate  are 
believed to decrease the methylation of HTR2A exon-1 and 
lead to increase in gene expression (Abdolmaleky et al. 
2015). Thus, taking into consideration of these limitations, 
further study should be done in a large sample size and the 
effect of antipsychotic medications on the methylation of 
AKT1 promoter as well as HTR2A exon-I should be 
investigated.
CONCLUSION
In conclusion, our study suggested that the methylation 
profiles on the studied CpG site of AKT1 promoter may 
associate with schizophrenia psychopathology and 
cognitive impairment. Moreover, inheritance of the altered 
methylation was observed within the majority of 
schizophrenia families. Our findings warrant further study 
involving the association of methylation of AKT1 promoter 
with its gene expression as well as their correlation with 
cognitive performance in schizophrenia patients. 
ACKNOWLEDGEMENTS
This study was financially supported by the UTARRF 
IPSR/RMC/UTARRF/2016-C1/T5 and Malaysia Toray 
Science Foundation 4417/T04, HIR/MOHE/MED/26. The 
authors would like to express deep gratitude to the 
psychiatrists and staffs of Hospital Permai, Johor Bahru, 
Malaysia for their assistance, as well as the patients and 
volunteer for their involvement in this study. 
REFERENCES
Abdolmaleky, H.M., Pajouhanfar, S., Faghankhani, M., 
Joghataei, M.T., Mostafavi, A. & Thiagalingam, S. 2015. 
Antipsychotic drugs attenuate aberrant DNA methylation of 
DTNBP1 (Dysbindin) promoter in saliva and post-mortem 
brain of patients with schizophrenia and psychotic bipolar 
disorder. American Journal of Medical Genetics Part B: 
Neuropsychiatric Genetics 168(8): 687-696. 
Abdolmaleky, H.M., Yaqubi, S., Papageorgis, P., Lambert, 
A.W., Ozturk, S., Sivaraman, V. & Thiagalingam, S. 2011. 
Epigenetic dysregulation of HTR2A in the brain of patients 
with schizophrenia and bipolar disorder. Schizophrenia 
Research 129(2-3): 183-190.
Abi-Saab, W.M., Bubser, M., Roth, R.H. & Deutch, A.Y. 1999. 
5-HT2 receptor regulation of extracellular GABA levels in 
the prefrontal cortex. Neuropsychopharmacology 20(1): 92-
96.
Bajestan, S.N., Sabouri, A.H., Nakamura, M., Takashima, H., 
Keikhaee, M.R., Behdani, F., Fayyazi, M.R., Sargolzaee, 
M.R., Bajestan, M.N., Sabouri, Z., Khayami, E., Haghighi, 
S., Hashemi, S.B., Eiraku, N., Tufani, H., Najmabadi, H., 
Arimura, K., Sano, A. & Osame, M. 2006. Association of 
AKT1 haplotype with the risk of schizophrenia in Iranian 
population. American Journal of Medical Genetics, Part B: 
Neuropsychiatric Genetics 141B(4): 383-386.
Balu, D.T., Carlson, G.C., Talbot, K., Kazi, H., Hill-Smith, T.E., 
Easton, R.M., Birnbaum, M.J. & Lucki, I. 2012. AKT1 
deficiency in schizophrenia and impairment of hippocampal 
plasticity and function. Hippocampus 22(2): 230-240. 
Bowie, C.R. & Harvey, P.D. 2006. Cognitive deficits and 
functional outcome in schizophrenia. Neuropsychiatric 
Disease and Treatment 2(4): 531-536. 
Chang, C.Y., Chen, Y.W., Wang, T.W. & Lai, W.S. 2016. 
Akting up in the GABA hypothesis of schizophrenia: 
AKT1 deficiency modulates GABAergic functions and 
hippocampus-dependent functions. Scientific Reports 6: 
33095. 
Cheah, S.Y., Lawford, B.R., Young, R.M., Morris, C.P. & 
Voisey, J. 2017. mRNA expression and DNA methylation 
analysis of serotonin receptor 2A (HTR2A) in the human 
schizophrenic brain. Genes 8(1): 1-11. 
Chouliaras, L., Pishva, E., Haapakoski, R., Zsoldos, E., 
Mahmood, A., Filippini, N., Burrage, J., Mill, J., Kivimäki, 
M., Lunnon, K. & Ebmeier, K.P. 2018. Peripheral DNA 
methylation, cognitive decline and brain aging: Pilot 
findings from the Whitehall II imaging study. Epigenomics 
10(5): 585-595. 
TABLE 5. Number of families with family members with the same methylation status
Gene Methylation statuses Scz (n =12) HC (n=12)
AKT1 (Chr14: 104796054) 
Unmethylated 0 (0.0%) 3 (25.0%)
Methylated 11 (91.7%) 7 (58.3%)
Mixed 1 (8.3%) 2 (16.7%)
HTR2A (Chr13: 46896918)
Unmethylated 4 (33.3%) 4 (33.3%)
Methylated 6 (50.0%) 2 (16.7%)
Mixed 2 (16.7%) 6 (50.0%)
HC: healthy control; n: family number; Scz: schizophrenia
641
Connor, C.M. & Akbarian, S. 2008. DNA methylation changes 
in schizophrenia and bipolar disorder. Epigenetics 3(2): 55-
58.
Dean, B. & Hayes, W. 1996. Decreased frontal cortical 
serotonin(2A) receptors in schizophrenia. Schizophrenia 
Research 21(3): 133-139. 
Dickinson, D., Ramsey, M.E. & Gold, J.M. 2007. Overlooking 
the obvious: A meta-analytic comparison of digit symbol 
coding tasks and other cognitive measures in schizophrenia. 
Archives of General Psychiatry 64(5): 532-542. 
Eggers, A.E. 2013. A serotonin hypothesis of schizophrenia. 
Medical Hypotheses 80(6): 791-794.
Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M. 
& Gogos, J.A. 2004. Convergent evidence for impaired 
AKT1-GSK3 β signaling in schizophrenia. Nature Genetics 
36(2): 131-137.
Frances, A. 2013. Saving normal: An insider’s revolt against 
out-of-control psychiatric diagnosis, DSM-5, big pharma 
and the medicalization of ordinary life. Psychotherapy in 
Australia 19(3): 14-18.
Garbett, K., Gal-Chis, R., Gaszner, G., Lewis, D.A. & Mirnics, 
K. 2008. Transcriptome alterations in the prefrontal cortex 
of subjects with schizophrenia who committed suicide. 
Neuropsychopharmacologia Hungarica 10(1): 9-14.
Gejman, P.V., Sanders, A.R. & Duan, J. 2010. The role of 
genetics in the etiology of schizophrenia. Psychiatric 
Clinics of North America 33(1): 35-66. 
Ghadirivasfi, M., Nohesara, S., Ahmad Khaniha, H.R., 
Eskandari, M.R., Mostafavi, S.,  Thiagalingam, S. & 
Abdolmaleky, H.M. 2011. Hypomethylation of the 
serotonin receptor type-2A Gene (HTR2A) at T102C 
polymorphic site in DNA derived from the saliva of patients 
with schizophrenia and bipolar disorder. American Journal 
of Medical Genetics Part B 156B(5): 536-545.
Gibney, E.R. & Nolan, C.M. 2010. Epigenetics and gene 
expression. Heredity 105(1): 4-13. 
González-Maeso, J., Weisstaub, N.V., Zhou, M., Chan, P., Ivic, 
L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., 
Sealfon, S.C. & Gingrich, J.A. 2007. Hallucinogens recruit 
specific cortical 5-HT2A receptor-mediated signaling 
pathways to affect behavior. Neuron 53(3): 439-452.
Green, M., Kern, R.S., Braff, D.L. & Mintz, J. 2000. 
Neurocognitive deficits and functional outcome in 
schizophrenia: Are we measuring the ‘right stuff’? 
Schizophrenia Bulletin 26(1): 119-136. 
Gu, L., Long, J., Yan, Y., Chen, Q., Pan, R., Xie, X., Mao, X., Hu, 
X., Wei, B. & Su, L. 2013. HTR2A-1438A/G polymorphism 
influences the risk of schizophrenia but not bipolar disorder 
or major depressive disorder: A meta-analysis. Journal of 
Neuroscience Research 91(5): 623-633. 
Herman, J.G. & Baylin, S.B. 2003. Gene silencing in cancer in 
association with promoter hypermethylation. New England 
Journal of Medicine 349(21): 2042-2054. 
Hurlemann, R., Matusch, A., Kuhn, K.U., Berning, J., 
Elmenhorst, D., Winz, O., Kolsch, H., Zilles, K., Wagner, 
M., Maier, W. & Bauer, A. 2008. 5-HT2A receptor density is 
decreased in the at-risk mental state. Psychopharmacology 
195(4): 579-590. 
Ikeda, M., Iwata, N., Suzuki, T., Kitajima, T., Yamanouchi, 
Y., Kinoshita, Y., Inada, T. & Ozaki, N. 2004. Association 
of AKT1 with schizophrenia confirmed in a Japanese 
population. Biological Psychiatry 56(9): 698-700. 
Jones, M.J., Farré, P., McEwen, L.M., Macisaac, J.L., Watt, K., 
Neumann, S.M., Emberly, E., Cynader, M.S., Virji-Babul, 
N. & Kobor, M.S. 2013. Distinct DNA methylation patterns 
of cognitive impairment and Trisomy 21 in down syndrome. 
BMC Medical Genomics 6: 58.
Jones, P.A. & Laird, P.W. 1999. Cancer epigenetics comes of 
age. Nature Genetics 21(2): 163-167.
Lam, L.L., Emberly, E., Fraser, H.B., Neumann, S.M., Chen, 
E., Miller, G.E. & Kobor, M.S. 2012. Factors underlying 
variable DNA methylation in a human community cohort. 
Proceedings of the National Academy of Sciences 109(2): 
17253-17560. 
Lee, S. & Huang, K. 2016. Epigenetic profiling of human brain 
differential DNA methylation networks in schizophrenia. 
BMC Medical Genomics 9(3): 217-228. 
Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, 
I., Jeppesen, P., Klein, F. & Bird, A. 1992. Purification, 
sequence, and cellular localization of a novel chromosomal 
protein that binds to methylated DNA. Cell 69(6): 905-
914.
Lezak, M.D. 1987. Assessment for rehabilitation planning. In 
Neuropsychological Rehabilitation, edited by Meier, M.J., 
Benton, A.L. & Diller, L. New York: Guilford Press. pp. 
41-58.
Long, M.D., Smiraglia, D.J. & Campbell, M.J. 2017. The 
genomic impact of DNA CpG methylation on gene 
expression: Relationships in prostate cancer. Biomolecules 
7(1): 1-20.
Marioni, R.E., Shah, S., McRae, A.F., Ritchie, S.J., Muniz-
Terrera, G., Harris, S.E., Gibson, J., Redmond, P., Cox, 
S.R., Pattie, A., Corley, J., Taylor, A., Murphy, L. Starr, 
J.M., Horvath, S., Visscher, P.M., Wray, N.R. & Deary, 
I.J. 2015. The epigenetic clock is correlated with physical 
and cognitive fitness in the Lothian Birth cohort 1936. 
International Journal of Epidemiology 44(4): 1388-1396. 
Mittal, P.K., Mehta, S., Solanki, R.K. & Swami, M.K. 2013. 
A comparative study of cognitive flexibility among first 
episode and multi-episode young schizophrenia patients. 
German Journal of Psychiatry 16(4): 130-136.
Monsell, S. 1996. Control of mental processes. In Unsolved 
Mysteries of the Mind: Tutorial Essays in Cognition, edited 
by Bruce, V. Oxford, England: Erlbaum (UK): Taylor & 
Francis. pp. 93-148.
Myers, R.L., Airey, D.C., Manier, D.H., Shelton, R.C. & 
Sanders-Bush, E. 2007. Polymorphisms in the regulatory 
region of the human serotonin 5-HT2A receptor gene 
(HTR2A) influence gene expression. Biol. Psychiatry 
61(12): 167-173. 
Nishioka, M., Bundo, M., Kasai, K. & Iwamoto, K. 2012. DNA 
methylation in schizophrenia: Progress and challenges of 
epigenetic studies. Genome Medicine 4(12): 1-13.
Perianez, J.A., Rios-Lago, M., Rodriguez-Sanchez, J.M., 
Adrover-Roig, D., Sanchez-Cubillo, I., Crespo-Facorro, 
B., Quemada, J.I. & Barcelo, F. 2007. Trail making test in 
traumatic brain injury, schizophrenia, and normal ageing: 
Sample comparisons and normative data. Archives of 
Clinical Neuropsychology 22(4): 433-447. 
Razin, A. & Cedar, H. 1991. DNA methylation and gene 
expression. Microbiological Reviews 55(3): 451-458. 
Reichenberg, A. & Harvey, P.D. 2007. Neuropsychological 
impairments in schizophrenia: Integration of performance-
based and brain imaging findings. Psychological Bulletin 
133(5): 833-858. 
Reitan, R.M. 1992. Trail Making Test: Manual for Administration 
and Scoring. Tucson, Arizona: Reitan Neuropsychology 
Laboratory.
642
Salleh, M.R. 2004. The genetics of schizophrenia. The 
Malaysian Journal of Medical Sciences: MJMS 11(2): 3-11. 
Salthouse, T.A. 2011. What cognitive abilities are involved in 
trail-Making performance? Intelligence 39(4): 222-232. 
Schmid, C.L. & Bohn, L.M. 2010. Serotonin, but not 
N-Methyltryptamines, activates the serotonin 2A receptor 
via a  β-Arrestin2/Src/Akt signaling complex in vivo. 
Journal of Neuroscience 30(40): 13513-13524.
Schwab, S.G., Hoefgen, B., Hanses, C., Hassenbach, M.B., 
Albus, M., Lerer, B., Trixler, M., Maier. & Wildenauer, 
D.B. 2005. Further evidence for association of variants in 
the AKT1 gene with schizophrenia in a sample of European 
sib-pair families. Biological Psychiatry 58(6): 446-450. 
Schwartz, T.L., Sachdeva, S. & Stahl, S.M. 2012. Glutamate 
neurocircuitry: Theoretical underpinnings in schizophrenia. 
Frontiers in Pharmacology 3: 195-205. 
Shen, R.Y. & Andrade, R. 1998. 5-Hydroxytryptamine2 
receptor facilitates GABAergic neurotransmission in rat 
hippocampus. Journal of Pharmacology and Experimental 
Therapeutics 285(2): 805-812.
Souza, B.R., Romano-Silva, M.A. & Tropepe, V. 2011. 
Dopamine D2 receptor activity modulates Akt signaling and 
alters GABAergic neuron development and motor behavior 
in Zebrafish larvae. The Journal of Neuroscience 31(14): 
5512-5525. 
Sujitha, S.P., Nair, A., Banerjee, M., Lakshmanan, S., 
Harshavaradhan, S., Gunasekaran, S. & Gopinathan, A. 
2014. 5-Hydroxytryptamine (Serotonin) 2A receptor gene 
polymorphism is associated with schizophrenia. Indian 
Journal of Medical Research 140(6): 736-743.
Tee, S.F., Chow, T.J., Tang, P.Y. & Loh, H.C. 2010. Linkage 
of schizophrenia with TPH2 and 5-HTR2A gene 
polymorphisms in the Malay population. Genetics and 
Molecular Research 9(3): 1274-1278. 
Thiselton, D.L., Vladimirov, V.I., Kuo, P.H., McClay, J., 
Wormley, B., Fanous, A., O’Neill, F.A., Walsh, D., Van den 
Oord, E.J.C.G., Kendler, K.S. & Riley, B.P. 2008. AKT1 
is associated with schizophrenia across multiple symptom 
dimensions in the Irish study of high density schizophrenia 
families. Biological Psychiatry 63(5): 449-457. 
Tombaugh, T.N. 2004. Trail making test A and B: Normative 
data stratified by age and education. Archives of Clinical 
Neuropsychology 19(2): 203-214. 
van Beveren, N.J.M., Buitendijk, G.H.S., Swagemakers, S., 
Krab, L.C., Röder, C., de Haan, L., van der Spek, P. & 
Elgersma, Y. 2012. Marked reduction of AKT1 expression 
and deregulation of AKT1-associated pathways in peripheral 
blood mononuclear cells of schizophrenia patients. PLoS 
ONE 7(2): e32618. 
Vanheule, S., Desmet, M., Meganck, R., Inslegers, R., 
Willemsen, J., De Schryver, M. & Devisch, I. 2014. 
Reliability in psychiatric diagnosis with the DSM: Old wine 
in new barrels. Psychotherapy and Psychosomatics 83(5): 
313-314.
Volk, D.W. & Lewis, D.A. 2005. GABA targets for the treatment 
of cognitive dysfunction in schizophrenia. Current 
Neuropharmacology 3(1): 45-62.
Williams, J., Spurlock, G., McGuffin, P., Mallet, J., Nothen, 
M.M., Gill, M., Aschauer, H., Nylander, P.O., Macciardi, 
F. & Owen, M.J. 1996. Association between schizophrenia 
and T102C polymorphism of the 5-hydroxytryptamine type 
2a-receptor gene. The Lancet 347(9011): 1294-1296.
Wockner, L.F., Noble, E.P., Lawford, B.R., Young, R., Morris, 
C.P.C., Whitehall, V.L.J. & Voisey, J. 2014. Genome-wide 
DNA methylation analysis of human brain tissue from 
schizophrenia patients. Translational Psychiatry 4: e339.
Zamani, A. & Qu, Z. 2012. Serotonin activates angiogenic 
phosphorylation signaling in human endothelial cells. FEBS 
Letters 586(16): 2360-2365.
Erna Laere & Shiau Foon Tee*
Lee Kong Chian, Faculty of Engineering and Science 
Department of Chemical Engineering 
Universiti Tunku Abdul Rahman
Jalan Sungai Long, Bandar Sungai Long 
Cheras 43000 Kajang, Selangor Darul Ehsan
Malaysia 
Tze Jen Chow & Pek Yee Tang
Lee Kong Chian, Faculty of Engineering and Science
Department of Mechatronics and Biomedical Engineering
Universiti Tunku Abdul Rahman 
Jalan Sungai Long, Bandar Sungai Long
Cheras 43000 Kajang, Selangor Darul Ehsan
Malaysia
Siew Yim Loh
Faculty of Medicine
University of Malaya 
50603 Kuala Lumpur, Federal Territory 
Malaysia
Hoi Sen Yong
Institute of Biological Sciences 
University of Malaya 
50603 Kuala Lumpur, Federal Territory 
Malaysia
Abdul Kadir, Abu Bakar
Jalan Persiaran Kempas Baru
81200 Johor Bahru, Johor Darul Takzim
Malaysia
*Corresponding author; email: teesf@utar.edu.my
Received: 2 October 2018
Accepted: 6 March 2019
